
Private equity · Buyout
LYFE Capital
LYFE Capital is a healthcare-focused investment platform with offices across Asia and the U.S., backing healthcare supply chain assets, product platforms and R&D services for institutional investors.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is LYFE Capital right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
Rounds LYFE Capital joined, from press and the firm’s own posts.
Every round LYFE Capital joined
Round sizes, LYFE Capital’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company LYFE Capital backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet LYFE Capital
Events where LYFE Capital’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
LYFE Capital is based in Grand Cayman, Cayman Islands. It also has offices in Menlo Park, Seoul, Shanghai, Tokyo and Singapore.
6 fund vehicles are on public registers (SEC adviser filings), including LYFE CAPITAL FUND IV (DRAGON), L.P., LYFE CAPITAL FUND III (DRAGON), L.P. and LYFE CAPITAL FUND IV (PHOENIX), L.P.
Stages: Buyout. Sectors: Biotech. From the firm’s own website.
LYFE Capital lists 14 portfolio companies on its website, including ST Pharm, Edge Medical, Profound Bio, Bora Pharmaceuticals and Brightech.
Firms whose websites list some of the same companies include 1955 Capital, HLC VGC MANAGEMENT IV LIMITED and Iaso Ventures.
Know before LYFE Capital’s next round is announced.
PRO tracks LYFE Capital’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.